Announcing Our Collaboration with Vistagen: Advancing Social Anxiety Disorder Research with Automated Insights

Jin Kim

February 25, 2025

•

min read

We are excited to announce our ongoing relationship with Vistagen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company committed to developing novel therapies for psychiatric and neurological disorders. Vistagen is currently conducting several Phase 3 clinical trials to evaluate its fasedienol nasal spray for the acute treatment of anxiety in adults with Social Anxiety Disorder — a condition affecting over 30 million adults in the United States alone.

‍

“*It is fabulous to have access to up-to-the-minute data integrated across multiple platforms, making it so much easier for our team to monitor trial progress!!,*” said Maura Maria, Senior Director of Clinical Operations at Vistagen.

‍

At Miracle, we are honored to support Vistagen by serving as a central “control room” across these studies, providing crucial visibility into clinical, operational, and recruitment metrics. By leveraging Miracle’s real-time dashboards and central access to metrics from disparate trial platforms (i.e. Electronic Data Capture,Randomization and Trial Supply Management, central lab system, recruitment, etc.), Vistagen reduces time spent on manual processes while gaining operational insights at their fingertips — optimizing clinical trial management and streamlining recruitment.

‍

“Since we started using the Miracle platform, gathering information for site interactions has become much more efficient. The intuitive interface allows us to quickly access recruitment and other performance metrics, lending to much more meaningful and actionable discussions with sites,” said Taryn Corriveau, Director of Clinical Operations at Vistagen.

‍

Looking Ahead

Our collaboration with Vistagen Therapeutics highlights Miracle’s role in accelerating clinical-stage research with real-time, data-driven insights. We are thrilled to support Vistagen in its goal of developing a new and innovative treatment for those whose lives are constrained by Social Anxiety Disorder, where a new treatment option has not been approved for over two decades.

‍

“With the Miracle platform we were able to go live very quickly, and the customization they continue to provide specific to our study designs has been invaluable,” said Josh Prince, Chief Operating Officer at Vistagen.

‍

As we continue to grow our work together, Miracle remains dedicated to delivering innovative solutions that streamline operations, empower data-driven decisions, and impact the future of clinical research.

‍

About Vistagen Therapeutics

With pioneering neuroscience and a deep understanding of nose-to-brain neurocircuitry, Vistagen is on a mission to develop and commercialize a new class of intranasal product candidates called “pherines” and establish new standards of care in the treatment of multiple psychiatric and neurological disorders that impact millions of people around the world. For more information, visit vistagen.com.

If you’d like to learn more about Vistagen’s clinical trials in Social Anxiety Disorder, please visit their study website for further details.

‍

‍About Miracle

Miracle is streamlining clinical trial management by serving as the control room in clinical trials. By consolidating data from multiple clinical trial platforms and delivering real-time, automated insights, Miracle empowers clinical-stage biopharma companies to cut inefficiencies, make data-driven decisions, and save time in clinical trials.

For more information, visit miracleml.com or contact us at sales[at]miracleml.com.

Jin Kim

Accelerating Rare Autoimmune Research: How Dianthus Therapeutics Leverages Miracle for Real-Time Insights

Dianthus Therapeutics uses Miracle to unify clinical trial data and accelerate decision-making in rare autoimmune research.